

Data Sharing Statement

Rosas IO, Bräu N, Waters M, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. DOI: 10.1056/NEJMoa2028700.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Complete de-identified patient data set
Additional information about data	—
How or where can the data be obtained?	https://vivli.org
When will data availability begin?	After publication
When will data availability end?	—
Will any supporting documents be available?	—

Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, go to https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm

This statement was posted on February 25, 2021, at NEJM.org.